Patients with prostate cancer who had multiple bone metastases
Conditions
Interventions
Degarelix, Denosumab, Enzarutamide, Radiation
Sponsors
Department of Urology, Gifu University Graduate School of Medicine Takuya Koie
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: histologically confirmed PCa with high burden synchronous metastatic disease (4 and more bone metastases), Eastern Cooperative Oncology Group performance status of 0-1, adequate bone marrow function (absolute neutrophil count 1500/m3 and more and platelet count 100000/m3 and more), adequate renal function (creatinine 2.0 mg/dL and less and/or creatinine clearance 40 mL/min and more), and adequate hepatic function (total bilirubin 1.5 mg/dL and less).
Exclusion criteria
Exclusion criteria: Patients who had previously undergone RT for the prostate or pelvis, or had received chemotherapy or hormonal therapy for PCa, were excluded. The patients who received finasteride or dutasteride before the surgery were also excluded from the present study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of this combination treatments on oncological outcomes | — |
Countries
Japan
Contacts
Public ContactMakoto Kawase
Gifu University Graduate School of Medicine Urology
Outcome results
None listed